Igenica Appoints Oncology Expert and Industry Veteran Gwen A. Fyfe, M.D. to Board of Directors

  Igenica Appoints Oncology Expert and Industry Veteran Gwen A. Fyfe, M.D. to
  Board of Directors

Business Wire

BURLINGAME, Calif. -- December 17, 2013

Igenica, Inc., a company focused on the discovery and development of
innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of
cancer, today announced the appointment of oncology expert and former
Genentech executive Gwen A. Fyfe, M.D., as an independent member of the
company’s Board of Directors.

“Gwen’s proven expertise overseeing the successful development of major
oncology drugs is invaluable to Igenica as we advance our pipeline, and most
imminently as we prepare to enter the clinic with our lead program, IGN523, in
early 2014,” said Mary Haak-Frendscho, Ph.D., chief executive officer of
Igenica. “Gwen’s appointment comes at a pivotal time in Igenica’s evolution as
we begin development of our first product candidate and expand our proprietary
platform to accelerate the development and delivery of effective homogeneous
ADC therapies that have enormous potential to address critical needs of cancer

Dr. Fyfe brings more than 20 years of drug development experience, including
key roles in the development and approvals of Rituxan^®, Herceptin^®,
Avastin^® and Tarceva^®. At Genentech, Inc. (now a member of the Roche Group),
she served as vice president, oncology development and vice president, Avastin
Franchise Team. She was a member of both the Development Oversight Committee
and the Research Review Committee, responsible for approving product
advancement from research into clinical development. Dr. Fyfe is a globally
recognized oncology expert and frequently invited member of National Cancer
Institute working groups and grant committees, American Society of Clinical
Oncologists oversight committees, and Institute of Medicine panels. She
currently serves on the Boards of Directors of Array BioPharma, Inc. and
Infinity Pharmaceuticals, Inc. Dr. Fyfe is a graduate of Washington University
School of Medicine and a board-certified pediatric oncologist.

“I am very pleased to join Igenica’s Board of Directors and have been
impressed with both Igenica’s platform technology and thehigh quality and
experience of its executive team,” saidDr. Fyfe. “The combination
ofanintegrated suite ofpipeline-enablingcapabilities and a proven team
oftherapeutic antibody leaderspositionsIgenicawell to drive
rapiddevelopment of high impact medicines.I look forward to collaborating
withthe Igenica team torealize themissionof delivering effective
biotherapeutics, including ADCs, to patientswith cancer.”

About Igenica, Inc.

Igenica, Inc. is focused on the discovery and development of antibodies and
antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the
only biotherapeutic company that fully powers the ADC development spectrum
from a patient-based approach to target and functional antibody discovery to
the generation and manufacturing of homogeneous ADCs. Igenica’s integrated
discovery engine has generated a robust pipeline of site-specific ADC
candidates and functional antibodies to address critical needs of cancer
patients. Led by a proven team of leaders with expertise in the development of
therapeutic antibodies and ADCs, Igenica is funded by a premier group of life
science investors including The Column Group, OrbiMed Advisors, 5AM Ventures
and Third Rock Ventures. For more information, please visit www.igenica.com.


Pure Communications Inc.
Katie Wilson, 910-509-3977
Press spacebar to pause and continue. Press esc to stop.